Research paper
Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia — significance for activation of the kynurenine pathway
Lilly Schwieler, Markus K. Larsson, Elisabeth Skogh, Magdalena E. Kegel, Funda Orhan, Sally Abdelmoaty, Anja Finn, Maria Bhat, Martin Samuelsson, Kristina Lundberg, Marja-Liisa Dahl, Carl Sellgren, Ina Schuppe-Koistinen, Camilla I. Svensson, Sophie Erhardt and Göran Engberg
J Psychiatry Neurosci March 01, 2015 40 (2) 126-133; DOI: https://doi.org/10.1503/jpn.140126
Lilly Schwieler
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDMarkus K. Larsson
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MScElisabeth Skogh
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MDMagdalena E. Kegel
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MScFunda Orhan
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MScSally Abdelmoaty
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDAnja Finn
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MScMaria Bhat
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
BScMartin Samuelsson
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MD, PhDKristina Lundberg
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MDMarja-Liisa Dahl
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MD, PhDCarl Sellgren
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
MD, PhDIna Schuppe-Koistinen
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDCamilla I. Svensson
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDSophie Erhardt
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDGöran Engberg
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
PhDArticle Information
vol. 40 no. 2 126-133
PubMed
History
- Received May 15, 2014
- Revision received August 13, 2014
- Accepted September 3, 2014
- Published online March 1, 2015.
Copyright & Usage
© 2015 8872147 Canada Inc.
Author Information
- Lilly Schwieler, PhD*,
- Markus K. Larsson, MSc*,
- Elisabeth Skogh, MD,
- Magdalena E. Kegel, MSc,
- Funda Orhan, MSc,
- Sally Abdelmoaty, PhD,
- Anja Finn, MSc,
- Maria Bhat, BSc,
- Martin Samuelsson, MD, PhD,
- Kristina Lundberg, MD,
- Marja-Liisa Dahl, MD, PhD,
- Carl Sellgren, MD, PhD,
- Ina Schuppe-Koistinen, PhD,
- Camilla I. Svensson, PhD,
- Sophie Erhardt, PhD,
- Göran Engberg, PhD⇑
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (Schwieler, Larsson, Kegel, Orhan, Abdelmoaty, Finn, Svensson, Erhardt, Engberg); Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden (Skogh, Samuelsson, Lundberg); AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden (Bhat, Schuppe-Koistinen); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Bhat, Schuppe-Koistinen); Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden (Dahl); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Sellgren).
- Correspondence to: G. Engberg, Department of Physiology and Pharmacology, Karolinska Institutet SE-171 77, Stockholm, Sweden; goran.engberg{at}ki.se
In this issue
Article tools
Respond to this article
Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia — significance for activation of the kynurenine pathway
Lilly Schwieler, Markus K. Larsson, Elisabeth Skogh, Magdalena E. Kegel, Funda Orhan, Sally Abdelmoaty, Anja Finn, Maria Bhat, Martin Samuelsson, Kristina Lundberg, Marja-Liisa Dahl, Carl Sellgren, Ina Schuppe-Koistinen, Camilla I. Svensson, Sophie Erhardt, Göran Engberg
J Psychiatry Neurosci Mar 2015, 40 (2) 126-133; DOI: 10.1503/jpn.140126
Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia — significance for activation of the kynurenine pathway
Lilly Schwieler, Markus K. Larsson, Elisabeth Skogh, Magdalena E. Kegel, Funda Orhan, Sally Abdelmoaty, Anja Finn, Maria Bhat, Martin Samuelsson, Kristina Lundberg, Marja-Liisa Dahl, Carl Sellgren, Ina Schuppe-Koistinen, Camilla I. Svensson, Sophie Erhardt, Göran Engberg
J Psychiatry Neurosci Mar 2015, 40 (2) 126-133; DOI: 10.1503/jpn.140126
Related Articles
- No related articles found.
Cited By...
- Cerebrospinal fluid concentration of complement component 4A is increased in first-episode schizophrenia
- A new schizophrenia model: immune activation is associated with induction of the tryptophan catabolite pathway and increased eotaxin levels which together determine memory impairments and schizophrenia symptom dimensions